Home/Pipeline/NIPAH Program

NIPAH Program

Nipah Virus Infection

Proof of ConceptActive

Key Facts

Indication

Nipah Virus Infection

Phase

Proof of Concept

Status

Active

Company

Fabentech

About Fabentech

Founded in 2007, Fabentech is a private, clinical-stage biotech focused on biodefense and pandemic preparedness. Its core asset is the FabShield® platform for generating polyclonal antibody fragment therapies against lethal biological agents. The company has a diversified pipeline targeting toxins and viruses, with one product (Ricimed®) approved, another in Phase 2 for COVID-19, and several earlier-stage programs backed by European and French defense agencies. Fabentech operates as a specialized contractor for government and public health preparedness markets.

View full company profile

Therapeutic Areas

Infectious Disease Biotoxicity Bioterrorism Countermeasures

Other Nipah Virus Infection Drugs

Drug	Company	Phase	Status
Nipah Virus Vaccine	Phylex BioSciences	Pre-clinical	Active
cVLP Nipah Virus Vaccine	AdaptVac	Pre-clinical	Active